Plasma Tumor Mutation Burden and Response to Pembrolizumab—Letter
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-20-0903
Abstract: Predictive biomarkers are critical for patient selection in immune checkpoint inhibitor (ICI) therapy. However, the term “predictive” are often confused with “prognostic,” leading to inappropriate treatment choice in clinical practice and research. We read with… read more here.
Keywords: burden response; tumor mutation; mutation burden; pembrolizumab letter ... See more keywords
Plasma Tumor Mutation Burden and Response to Pembrolizumab—Response
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-20-1073
Abstract: We have carefully reviewed the letter from Li and colleagues and believe that there were misunderstandings of the results and interpretation of the findings, which we would like to take the opportunity to clarify. We… read more here.
Keywords: burden response; response; tumor mutation; mutation burden ... See more keywords